Microorganism |
|
|
|
Antimicrobial |
|
|
Reference |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.015 |
0.03 |
0.015 - 0.03 |
AC98-6446 |
175 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.015 |
0.5 |
≤0.004 - 4 |
Gemifloxacin |
268 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.03 |
0.06 |
≤0.015 - 0.06 |
Dalbavancin |
72 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.03 |
0.12 |
≤0.03 - 0.5 |
Imipenem |
371 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.03 |
0.5 |
≤0.016 - 2 |
Moxifloxacin (BAY 12-8039, Avelox) |
207 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.03 |
0.5 |
0.12 - 1 |
DC-159a |
268 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.03 |
1 |
0.015 - 8 |
Garenoxacin (T-3811, BMS-284756) |
268 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
≤0.06 |
≤0.06 |
≤0.06 - >16 |
Gentamicin (Gentamycin, Garamycin) |
73 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.06 |
0.12 |
0.008 - 1 |
Imipenem |
102 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.06 |
0.12 |
0.015 - 4 |
Garenoxacin (T-3811, BMS-284756) |
102 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.06 |
0.12 |
0.03 - >128 |
Telithromycin (HMR 3647, RU-66647, Ketek) |
162 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.06 |
0.25 |
≤0.06 - 0.5 |
TAK-599 |
162 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.06 |
0.5 |
≤0.03 - >8 |
Telithromycin (HMR 3647, RU-66647, Ketek) |
73 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.06 |
1 |
0.03 - 4 |
Gatifloxacin (Tequin) |
207 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.06 |
1 |
0.03 - 8 |
Moxifloxacin (BAY 12-8039, Avelox) |
268 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.12 |
0.12 |
≤0.06 - 0.25 |
Oxacillin (Prostaphilin, Bactocil, Prostaphlin) |
73 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
≤0.12 |
≤0.12 |
≤0.12 - 0.25 |
Gentamicin (Gentamycin, Garamycin) |
89 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.12 |
0.25 |
0.06 - 0.25 |
Levofloxacin (Levaquin, Quixin) |
16 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.12 |
0.25 |
0.06 - 0.5 |
Daptomycin (Cubicin) |
16 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.12 |
0.25 |
0.06 - 4 |
Moxifloxacin (BAY 12-8039, Avelox) |
102 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.12 |
0.25 |
0.06 - 8 |
Sparfloxacin (AT-4140, Zagam) |
117 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.12 |
0.25 |
≤0.12 - 0.25 |
Quinupristin/Dalfopristin (Synercid) |
73 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.12 |
0.25 |
≤0.12 - >64 |
Clindamycin (Cleocin) |
371 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.12 |
0.5 |
≤0.06 - 1 |
Ranbezolid (RBX 7644) |
162 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.12 |
8 |
≤0.12 - >64 |
Erythromycin (E-mycin, Ery-tab, Benzamycin) |
371 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.123 |
0.625 |
? - ? |
Ceftobiprole (Zeftera) |
942 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.125 |
0.5 |
≤0.06 - 1 |
Quinupristin/Dalfopristin (Synercid) |
207 |
Staphylococci (coagulase-negative + methicillin-susceptible) |
0.125 |
0.5 |
≤0.06 - 1 |
Quinupristin/Dalfopristin (Synercid) |
72 |